Skip to main content
Erschienen in: Der Hautarzt 2/2007

01.02.2007 | Leitthema

Anti-Interleukin-5-Therapie bei eosinophilen Erkrankungen

verfasst von: PD Dr. D. Simon, L.R. Braathen, H.-U. Simon

Erschienen in: Die Dermatologie | Ausgabe 2/2007

Einloggen, um Zugang zu erhalten

Zusammenfassung

Bei einer Reihe von Erkrankungen, die durch eine Eosinophilie charakterisiert sind, findet man erhöhte Spiegel von Interleukin- (IL-)5 im Blut und/oder Gewebe. IL-5 spielt eine wichtige Rolle in der Regulierung von Produktion, Differenzierung, Rekrutierung, Aktivierung und Überleben eosinophiler Granulozyten. Daher stellt die Neutralisation von IL-5 durch blockierende Antikörper einen vielversprechenden neuen Ansatz in der Therapie dieser Erkrankungen dar. Erste klinische Studien zeigten, dass es nach Applikation von Anti-IL-5-Antikörpern zu einem raschen Abfall der Eosinophilenzahlen im peripheren Blut kommt. Eine Abnahme der Beschwerden wurde bei der lymphozytären Form hypereosinophiler Syndrome, bei eosinophiler Ösophagitis und bei chronischer Rhinitis mit nasaler Polyposis beobachtet. Im Gegensatz dazu zeigte eine Anti-IL-5-Antikörper-Behandlung von Patienten mit Asthma bronchiale oder mit atopischem Ekzem nicht den erwarteten klinischen Effekt. Zukünftige Studien werden zeigen, bei welchen eosinophilen Erkrankungen eine Anti-IL-5-Therapie wirksam ist und welche Patientengruppen auf diese Therapie ansprechen.
Literatur
1.
Zurück zum Zitat Akdis CA, Akdis M, Simon D et al. (1999) T cells and T cell-derived cytokines as pathogenic factors in the nonallergic form of atopic dermatitis. J Invest Dermatol 113: 628–634CrossRefPubMed Akdis CA, Akdis M, Simon D et al. (1999) T cells and T cell-derived cytokines as pathogenic factors in the nonallergic form of atopic dermatitis. J Invest Dermatol 113: 628–634CrossRefPubMed
2.
Zurück zum Zitat Arora AS, Yamazaki K (2004) Eosinophilic esophagitis: asthma of the esophagus. Clin Gastroenterol Hepatol 2: 523–530CrossRefPubMed Arora AS, Yamazaki K (2004) Eosinophilic esophagitis: asthma of the esophagus. Clin Gastroenterol Hepatol 2: 523–530CrossRefPubMed
3.
Zurück zum Zitat Buttner C, Lun A, Splettstoesser T et al. (2003) Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions. Eur Respir J 21: 799–803CrossRefPubMed Buttner C, Lun A, Splettstoesser T et al. (2003) Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions. Eur Respir J 21: 799–803CrossRefPubMed
4.
Zurück zum Zitat Cheng JF, Ott NL, Peterson EA et al. (1997) Dermal eosinophils undergo cytolytic degeneration. J Allergy Clin Immunol 99: 683–692CrossRefPubMed Cheng JF, Ott NL, Peterson EA et al. (1997) Dermal eosinophils undergo cytolytic degeneration. J Allergy Clin Immunol 99: 683–692CrossRefPubMed
5.
Zurück zum Zitat Chusid MJ, Dale DC, West BC, Wolff SM (1975) The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 54: 1–27 Chusid MJ, Dale DC, West BC, Wolff SM (1975) The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 54: 1–27
6.
Zurück zum Zitat Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS (2003) Eosinophil’s role remains uncertain as anti-IL-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 167: 199–204CrossRefPubMed Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS (2003) Eosinophil’s role remains uncertain as anti-IL-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 167: 199–204CrossRefPubMed
7.
Zurück zum Zitat Garrett JK, Jameson SC, Thomson B et al. (2004) Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol 113: 115–119CrossRefPubMed Garrett JK, Jameson SC, Thomson B et al. (2004) Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol 113: 115–119CrossRefPubMed
8.
Zurück zum Zitat Geveart P, Lang-Loidolt D, Lackner A et al. (2006) Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol 118: 1133–1141CrossRefPubMed Geveart P, Lang-Loidolt D, Lackner A et al. (2006) Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol 118: 1133–1141CrossRefPubMed
9.
Zurück zum Zitat Gleich GJ (2000) Mechanisms of eosinophil-associated inflammation. J Allergy Clin Immunol 105: 651–663CrossRefPubMed Gleich GJ (2000) Mechanisms of eosinophil-associated inflammation. J Allergy Clin Immunol 105: 651–663CrossRefPubMed
10.
Zurück zum Zitat Gregory B, Kirchem A, Phipps S et al. (2003) Differential regulation of human eosinophil IL-3, IL-5, and GM-CSF receptor α-chain expression by cytokines: IL-3, IL-5, and GM-CSF down-regulate IL-5 receptor α expression with loss of IL-5 responsiveness, but up-regulate IL-3 receptor α expression. J Immunol 170: 5359–5366PubMed Gregory B, Kirchem A, Phipps S et al. (2003) Differential regulation of human eosinophil IL-3, IL-5, and GM-CSF receptor α-chain expression by cytokines: IL-3, IL-5, and GM-CSF down-regulate IL-5 receptor α expression with loss of IL-5 responsiveness, but up-regulate IL-3 receptor α expression. J Immunol 170: 5359–5366PubMed
11.
Zurück zum Zitat Hamelman E, Gelfand EW (2001) IL-5-induced airway eosinophilia-the key to asthma? Immunol Rev 179: 182–191CrossRefPubMed Hamelman E, Gelfand EW (2001) IL-5-induced airway eosinophilia-the key to asthma? Immunol Rev 179: 182–191CrossRefPubMed
12.
Zurück zum Zitat Hart TK, Cook RM, Zia-Amirhosseini P et al. (2001) Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. J Allergy Clin Immunol 108: 250–257CrossRefPubMed Hart TK, Cook RM, Zia-Amirhosseini P et al. (2001) Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. J Allergy Clin Immunol 108: 250–257CrossRefPubMed
13.
Zurück zum Zitat Kiehl P, Falkenberg K, Vogelbruch M, Kapp A (2001) Tissue eosinophilia in acute and chronic dermatitis: a morphometric approach using quantitative image analysis of immunostaining. Br J Dermatol 145: 720–729CrossRefPubMed Kiehl P, Falkenberg K, Vogelbruch M, Kapp A (2001) Tissue eosinophilia in acute and chronic dermatitis: a morphometric approach using quantitative image analysis of immunostaining. Br J Dermatol 145: 720–729CrossRefPubMed
14.
Zurück zum Zitat Kips JC, O’Connor BJ, Langley SJ et al. (2003) Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistant asthma: a pilot study. Am J Respir Crit Care Med 167: 1655–1659CrossRefPubMed Kips JC, O’Connor BJ, Langley SJ et al. (2003) Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistant asthma: a pilot study. Am J Respir Crit Care Med 167: 1655–1659CrossRefPubMed
15.
Zurück zum Zitat Klion A, Nutman TB (2004) The role of eosinophils in host defense against helminth parasites. J Allergy Clin Immunol 113: 30–37CrossRefPubMed Klion A, Nutman TB (2004) The role of eosinophils in host defense against helminth parasites. J Allergy Clin Immunol 113: 30–37CrossRefPubMed
16.
Zurück zum Zitat Leckie MJ, ten Brinke A, Khan J et al. (2000) Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356: 2144–2148CrossRefPubMed Leckie MJ, ten Brinke A, Khan J et al. (2000) Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356: 2144–2148CrossRefPubMed
17.
Zurück zum Zitat Leifermann KM, Ackermann SJ, Sampson HA et al. (1985) Dermal deposition of eosinophil-granule major basic protein in atopic dermatitis: comparison with onchocerciasis. N Engl J Med 313: 282–285PubMed Leifermann KM, Ackermann SJ, Sampson HA et al. (1985) Dermal deposition of eosinophil-granule major basic protein in atopic dermatitis: comparison with onchocerciasis. N Engl J Med 313: 282–285PubMed
18.
Zurück zum Zitat Mattes J, Yang M, Mahalingam S et al. (2002) Intrinsic defect in T cell production of interleukin (IL)-13 in the abscence of both IL-5 and eotaxin precludes the development of eosinophilia and airway hyperreactivity in experimental asthma. J Exp Med 195: 1433–1444CrossRefPubMed Mattes J, Yang M, Mahalingam S et al. (2002) Intrinsic defect in T cell production of interleukin (IL)-13 in the abscence of both IL-5 and eotaxin precludes the development of eosinophilia and airway hyperreactivity in experimental asthma. J Exp Med 195: 1433–1444CrossRefPubMed
19.
Zurück zum Zitat Menzies-Gow A, Flood-Page P, Sehmai R et al. (2003) Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. J Allergy Clin Immunol 111: 714–719CrossRefPubMed Menzies-Gow A, Flood-Page P, Sehmai R et al. (2003) Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. J Allergy Clin Immunol 111: 714–719CrossRefPubMed
20.
Zurück zum Zitat Mishra A, Rothenberg ME (2003) Intratracheal IL-13 induces eosinophilic esophagitis by an IL-5, eotaxin-1, and STAT6-dependent manner. Gastroenterology 125: 1419–1427CrossRefPubMed Mishra A, Rothenberg ME (2003) Intratracheal IL-13 induces eosinophilic esophagitis by an IL-5, eotaxin-1, and STAT6-dependent manner. Gastroenterology 125: 1419–1427CrossRefPubMed
21.
Zurück zum Zitat Oldhoff JM, Darsow U, Werfel T et al. (2005) Anti-IL-5 recombinant humanized monoclonal antibody (Mepolizumab) for the treatment of atopic dermatitis. Allergy 60: 693–696CrossRefPubMed Oldhoff JM, Darsow U, Werfel T et al. (2005) Anti-IL-5 recombinant humanized monoclonal antibody (Mepolizumab) for the treatment of atopic dermatitis. Allergy 60: 693–696CrossRefPubMed
22.
Zurück zum Zitat Phipps S, Flood-Page P, Menzies-Gow A et al. (2004) Intravenous anti-IL-5 monoclonal antibody reduces eosinophils and tenascin deposition in allergen-challenged human atopic skin. J Invest Dermatol 122: 1406–1412CrossRefPubMed Phipps S, Flood-Page P, Menzies-Gow A et al. (2004) Intravenous anti-IL-5 monoclonal antibody reduces eosinophils and tenascin deposition in allergen-challenged human atopic skin. J Invest Dermatol 122: 1406–1412CrossRefPubMed
23.
Zurück zum Zitat Plötz SG, Simon HU, Darsow U, Simon D, Vassina E, Yousefi S, Hein R, Smith T, Behrendt H, Ring J (2003) Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 349:2332–2337. Plötz SG, Simon HU, Darsow U, Simon D, Vassina E, Yousefi S, Hein R, Smith T, Behrendt H, Ring J (2003) Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 349:2332–2337.
24.
Zurück zum Zitat Simon D, Braathen LR, Simon HU (2004) Eosinophils and atopic dermatitis. Allergy 59: 561–570CrossRefPubMed Simon D, Braathen LR, Simon HU (2004) Eosinophils and atopic dermatitis. Allergy 59: 561–570CrossRefPubMed
25.
Zurück zum Zitat Simon D, Vassina E, Yousefi S et al. (2004) Reduced dermal infiltration of cytokine-expressing cells in atopic dermatitis following short-term topical tacrolimus treatment. J Allergy Clin Immunol 114: 887–895CrossRefPubMed Simon D, Vassina E, Yousefi S et al. (2004) Reduced dermal infiltration of cytokine-expressing cells in atopic dermatitis following short-term topical tacrolimus treatment. J Allergy Clin Immunol 114: 887–895CrossRefPubMed
26.
Zurück zum Zitat Simon D, Vassina E, Yousefi S et al. (2005) Inflammatory cell numbers and cytokine expression in atopic dermatitis after topical pimecrolimus treatment. Allergy 60: 944–951CrossRefPubMed Simon D, Vassina E, Yousefi S et al. (2005) Inflammatory cell numbers and cytokine expression in atopic dermatitis after topical pimecrolimus treatment. Allergy 60: 944–951CrossRefPubMed
27.
Zurück zum Zitat Simon D, Marti H, Heer P et al. (2005) Eosinophilic esophagitis is frequently associated with IgE-mediated allergic airway diseases. J Allergy Clin Immunol 115: 1090–1092CrossRefPubMed Simon D, Marti H, Heer P et al. (2005) Eosinophilic esophagitis is frequently associated with IgE-mediated allergic airway diseases. J Allergy Clin Immunol 115: 1090–1092CrossRefPubMed
28.
Zurück zum Zitat Simon HU (1998) Eosinophil apoptosis in allergic diseases – an emerging new issue. Clin Exp Allergy 28: 1321–1324CrossRefPubMed Simon HU (1998) Eosinophil apoptosis in allergic diseases – an emerging new issue. Clin Exp Allergy 28: 1321–1324CrossRefPubMed
29.
Zurück zum Zitat Simon HU, Plötz SG, Dummer R, Blaser K (1999) Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 341: 1112–1120CrossRefPubMed Simon HU, Plötz SG, Dummer R, Blaser K (1999) Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 341: 1112–1120CrossRefPubMed
30.
Zurück zum Zitat Straumann A, Bauer M, Fischer B et al. (2001) Idiopathic eosinophilic esophagitis is associated with a T(H)2-type allergic inflammatory response. J Allergy Clin Immunol 108: 954–961CrossRefPubMed Straumann A, Bauer M, Fischer B et al. (2001) Idiopathic eosinophilic esophagitis is associated with a T(H)2-type allergic inflammatory response. J Allergy Clin Immunol 108: 954–961CrossRefPubMed
31.
Zurück zum Zitat Straumann A, Spichtin HP, Grize L et al. (2003) Natural history of primary eosinophilic esophagitis: a follow-up of 30 adult patients for up to 11.5 years. Gastroenterology 125: 1660–1669CrossRefPubMed Straumann A, Spichtin HP, Grize L et al. (2003) Natural history of primary eosinophilic esophagitis: a follow-up of 30 adult patients for up to 11.5 years. Gastroenterology 125: 1660–1669CrossRefPubMed
32.
Zurück zum Zitat Straumann A, Simon HU (2004) The physiological and pathophysiological roles of eosinophils in the gastrointestinal tract. Allergy 59: 15–25CrossRefPubMed Straumann A, Simon HU (2004) The physiological and pathophysiological roles of eosinophils in the gastrointestinal tract. Allergy 59: 15–25CrossRefPubMed
33.
Zurück zum Zitat Wang J, Palmer K, Lötvall J et al. (1998) Circulating, but not local lung, IL-5 is required for the development of antigen-induced airway eosinophilia. J Clin Invest 102: 1132–1141PubMed Wang J, Palmer K, Lötvall J et al. (1998) Circulating, but not local lung, IL-5 is required for the development of antigen-induced airway eosinophilia. J Clin Invest 102: 1132–1141PubMed
34.
Zurück zum Zitat Zhang J, Kuvelkar R, Murgolo NJ et al. (1999) Mapping and characterization of the epitope(s) of Sch 55700, a humanized mAb, that inhibits human IL-5. Int Immunol 11: 1935–1944CrossRefPubMed Zhang J, Kuvelkar R, Murgolo NJ et al. (1999) Mapping and characterization of the epitope(s) of Sch 55700, a humanized mAb, that inhibits human IL-5. Int Immunol 11: 1935–1944CrossRefPubMed
Metadaten
Titel
Anti-Interleukin-5-Therapie bei eosinophilen Erkrankungen
verfasst von
PD Dr. D. Simon
L.R. Braathen
H.-U. Simon
Publikationsdatum
01.02.2007
Verlag
Springer-Verlag
Erschienen in
Die Dermatologie / Ausgabe 2/2007
Print ISSN: 2731-7005
Elektronische ISSN: 2731-7013
DOI
https://doi.org/10.1007/s00105-006-1273-x

Weitere Artikel der Ausgabe 2/2007

Der Hautarzt 2/2007 Zur Ausgabe

CME Weiterbildung • Zertifizierte Fortbildung

Differenzialdiagnose des atopischen Ekzems in der Kindheit

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.